Primer: Maze Therapeutics (MAZE US) - Aug 2026
Maze Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary Compass™ platform, which integrates human genetics...
108 Views
Aardvark Therapeutics (AARD) Six Month Summary: A Cold Debut That Froze the Biotech Market
​Aardvark's biotech IPO priced at low end, opened underwater, highlighting lack of sector interest and market freeze in 2025.
482 Views
Sionna Therapeutics (SION) Six Month Summary: Hot Start, Cold Reality, and a Strong Spring Rebound
​Sionna Therapeutics' successful IPO sees strong market debut with 38.9% premium, fueled by positive Phase I data for Metsera.
425 Views
Metsera Inc (MTSR) Six Month Summary: The Bright Spot in a Quiet Biotech Year
​Metsera's stock offering priced above range, shares rally to $47.40, trajectory hinges on upcoming clinical trial data for MET-233i.
391 Views
Maze Therapeutics (MAZE) Six Month Summary: A Volatile Debut with High-Stakes Catalysts Ahead
​Maze prices upsized IPO, opens at slight premium but has traded below issue for the majority of its life as a public company; future hinges on...
413 Views